Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 32Carboplatin 23liposomal doxorubicin 14pembrolizumab 12Topotecan 10Bevacizumab 10Gemcitabine 9mirvetuximab soravtansine 8olaparib 6Cisplatin 61-dodecylpyridoxal 6rucaparib 5Nivolumab 5Cyclophosphamide 5oregovomab 4farletuzumab 3catumaxomab 3Standard of Care 3Irinotecan 3Fulvestrant 3CCV-AV protocol 3talazoparib 2sacituzumab govitecan 2ribociclib 2phenoxodiol 2pegfilgrastim 2pazopanib 2palbociclib 2niraparib 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ovarian Epithelial × Vascular Endothelial Growth Factor A × Clear all
NCT01551745 2021-10-19

Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab

Gradalis, Inc.

Phase 2 Completed
5 enrolled 9 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡